# Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

> **NCT00889525** · PHASE3 · COMPLETED · sponsor: **Seth Gordhandas Sunderdas Medical College**

## Conditions studied

- Cushing's Disease
- Corticotroph Adenoma

## Interventions

- **DRUG:** Cabergoline

## Key facts

- **NCT ID:** NCT00889525
- **Lead sponsor:** Seth Gordhandas Sunderdas Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2009-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00889525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00889525, "Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00889525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*